Scott Turicchi - j2 Global, Inc.
Analyst · SIG. Please proceed.
Well, I'll answer some of your questions, some of your questions I'm not going to answer. If I don't answer them, remind me, and I'll tell you that I'm not answering them, because I can't remember all the questions you just asked. So let's take them in reverse order. Everyday Health contributed in the slightly less than a month that we owned it about $23 million of revs and about $7.5 million of EBITDA. In terms of the way we look at the business and the way we construct our guidance, all five business units are included in 2017 guidance. So that includes the consumer piece, which is Everyday Health and Mayo, the doctor's piece, which is MedPages, the What to Expect piece, which is focusing on primarily pregnancy, and then Cambridge, which is for orphan drugs, and Tea Leaves, which is SaaS CRM systems for hospitals. So all five of those units that we bought are included in our guidance. As I mentioned, the latter two units are the ones that have about 20% of total revenue, but not a lot of contribution in EBITDA, in large part due to Tea Leaves, which is really a almost venture capital type investment with a very strong growth profile, but currently not making any money. And quite frankly, not likely to do so, because it needs to continue to be fed. Now, as we mentioned on December, and I think we mentioned it about a month or so ago when Vivek and I were presenting on the Needham Conference in New York, even prior to closing the acquisition, third parties approached us about acquiring certain of the portfolio of assets that we bought. And our view was that might be of interest, but right now, we got to close the deal and we've got to take our initial steps. Once that settles down, then we'd be happy to see whether that makes sense. We are approaching that phase of seeing whether those inbound inquires would make sense for us in terms of whether we would keep those assets or not. At this point, I think it's too early to tell or to make any determination as to whether any of these interested parties are real or if the level of their potential offers would be acceptable to us. In terms of what they are worth, no, I'm not going to tell you that. We have our number and that will come out in time if either one or both of those assets were sold.